Iptacopan hydrochloride

盐酸伊普可泮

Report date: 2026/05/12 20:00:17
NMEFirst In Class

Base Information

Drug NameIptacopan hydrochloride
Drug Alias NameIptacopan伊普可泮Iptacopan hydrochloride monohydrateFabhaltaFABHALTA +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsC3 glomerulopathyPurpura, Thrombocytopenic, IdiopathicHemoglobinuria, Paroxysmal +[16] 
Global Approved IndicationsHemoglobinuria, Paroxysmal
Approved Indications in ChinaHemoglobinuria, Paroxysmal
Original Approved Country/TerritoryUnited States
Original Approved Date2023/12/05
Country/TerritoryCzechiaBelgiumCanada +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Produktions GmbhNovartis Pharma Schweiz AgNovartis Pharma Ag +[6] 
Inactive CompaniesBeijing Novartis Pharma Co Ltd
Active IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalProteinuria +[14] 
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicClostridium Infections

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG